Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the first quarter, Holdings Channel reports. The firm owned 1,039,519 shares of the company’s stock after buying an additional 40,509 shares during the quarter. Johnson & Johnson accounts for 1.3% of Zurcher Kantonalbank Zurich Cantonalbank’s investment portfolio, making the stock its 10th biggest holding. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Johnson & Johnson were worth $136,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also modified their holdings of the company. Exchange Traded Concepts LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $31,000. University of Texas Texas AM Investment Managment Co. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $31,000. Advocacy Wealth Management Services LLC lifted its stake in shares of Johnson & Johnson by 38.2% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock worth $39,000 after acquiring an additional 83 shares during the period. Lion Street Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $45,000. Finally, Joseph P. Lucia & Associates LLC lifted its stake in shares of Johnson & Johnson by 50.8% in the 1st quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock worth $49,000 after acquiring an additional 126 shares during the period. Hedge funds and other institutional investors own 67.66% of the company’s stock.
Several analysts have recently commented on the stock. UBS Group cut shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. Barclays raised their price objective on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Argus reiterated a “buy” rating and issued a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Finally, Raymond James raised their price objective on shares of Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $163.47.
NYSE:JNJ opened at $144.37 on Friday. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $146.81 and a two-hundred day moving average price of $142.30. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a market capitalization of $386.52 billion, a P/E ratio of 19.10, a price-to-earnings-growth ratio of 3.19 and a beta of 0.71.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The firm had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. During the same period last year, the firm posted $2.10 EPS. The firm’s revenue for the quarter was up 3.3% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 7.68 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 annualized dividend and a yield of 2.80%. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 43.78%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What is the LIBOR?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.